Jachimowicz, R. D.; Engert, A.: The challenging aspects of managing adolescents and young adults with Hodgkin's lymphoma. Acta Haematol 132 (3-4), S. 274 - 8 (2014)

Jachimowicz, R. D.; Borchmann, S.; Rothe, A.: Multi-specific antibodies for cancer immunotherapy. BioDrugs 28 (4), S. 331 - 43 (2014)

Dietlein, F.; Thelen, L.; Jokic, M.; Jachimowicz, R. D.; Ivan, L.; Knittel, G.; Leeser, U.; van Oers, J.; Edelmann, W.; Heukamp, L. C. et al.; Reinhardt, H. C.: A functional cancer genomics screen identifies a druggable synthetic lethal interaction between MSH3 and PRKDC. Cancer Discov 4 (5), S. 592 - 605 (2014)

Rothe, A.; Jachimowicz, R. D.; Borchmann, S.; Madlener, M.; Kessler, J.; Reiners, K. S.; Sauer, M.; Hansen, H. P.; Ullrich, R. T.; Chatterjee, S. et al.; Borchmann, P.; Yazaki, P.; Koslowsky, T. C.; Engert, A.; Heukamp, L. C.; Hallek, M.; von Strandmann, E. P.: The bispecific immunoligand ULBP2-aCEA redirects natural killer cells to tumor cells and reveals potent anti-tumor activity against colon carcinoma. Int J Cancer 134 (12), S. 2829 - 40 (2013)

Sauer, M.; Plutschow, A.; Jachimowicz, R. D.; Kleefisch, D.; Reiners, K. S.; Ponader, S.; Engert, A.; von Strandmann, E. P.: Baseline serum TARC levels predict therapy outcome in patients with Hodgkin lymphoma. Am J Hematol 88 (2), S. 113 - 5 (2012)

Jachimowicz, R. D.; Fracasso, G.; Yazaki, P. J.; Power, B. E.; Borchmann, P.; Engert, A.; Hansen, H. P.; Reiners, K. S.; Marie, M.; von Strandmann, E. P. et al.; Rothe, A.: Induction of in vitro and in vivo NK cell cytotoxicity using high-avidity immunoligands targeting prostate-specific membrane antigen in prostate carcinoma. Mol Cancer Ther 10 (6), S. 1036 - 45 (2011)